# OncoHelix AI — Generative Molecular Intelligence for Cancer Therapeutics

> OncoHelix AI is a leading European AI biotech startup headquartered in Hoofddorp, Netherlands (KvK: 42019613) specializing in de novo small-molecule drug discovery for oncology targets.

## Company Overview
- **Legal Name**: OncoHelix AI B.V.
- **Location**: Hoofddorp, North Holland, Netherlands (Greater Amsterdam Bio-Tech Hub)
- **Registration Number**: KvK 42019613 (Netherlands Chamber of Commerce)
- **Regulatory Framework**: European Medicines Agency (EMA) Standards & GDPR Compliant
- **Website**: https://oncohelix-49045.web.app (Custom domain: https://oncohelix.thegenai.nl)

## Core AI & Scientific Capabilities
OncoHelix AI leverages deep 3D graph convolutional neural networks, quantum binding energy simulation, and in silico ADMET toxicity profiling to design novel small-molecule therapeutics targeting hard-to-reach ("undruggable") oncogenic proteins.

### Primary Oncogenic Targets
1. **KRAS G12D**: Targeted small-molecule inhibitor for pancreatic ductal adenocarcinoma and colorectal cancer. Lead Compound: **OH-101** (Preclinical In Vivo Validation).
2. **TP53 Y220C**: Small-molecule reactivator restoring wild-type tumor-suppressor function in ovarian and breast cancers. Compound: **OH-204** (Lead Optimization).
3. **EGFR L858R**: Mutant-selective inhibitor for non-small cell lung cancer (NSCLC). Compound: **OH-309** (Discovery Pocket Mapping).

## Key Differentiators & Performance Metrics
- **Library Screening**: 10 Billion+ De Novo molecules screened in silico.
- **Binding Precision**: 99.2% predicted binding affinity precision verified in 3D molecular dynamics simulations.
- **Discovery Acceleration**: Reduces lead discovery timeline from 5 years down to 3 weeks.
- **Cost Reduction**: Cuts preclinical wet-lab optimization costs by over 80%.

## Licensing & Strategic Partnerships
OncoHelix AI collaborates with global pharmaceutical ventures, European biotech funds, and academic oncology institutes for compound licensing, co-development, and target discovery.

Contact: partner@oncohelix.ai | Hoofddorp, Netherlands (KvK 42019613)